<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/069AABE7-ED6F-470F-9A25-F547706D30E3"><gtr:id>069AABE7-ED6F-470F-9A25-F547706D30E3</gtr:id><gtr:name>University of Sri Jayewardenepura</gtr:name><gtr:address><gtr:line1>Gangodawila</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/069AABE7-ED6F-470F-9A25-F547706D30E3"><gtr:id>069AABE7-ED6F-470F-9A25-F547706D30E3</gtr:id><gtr:name>University of Sri Jayewardenepura</gtr:name><gtr:address><gtr:line1>Gangodawila</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C2464840-7606-47D9-AE5C-D1A6A69906BC"><gtr:id>C2464840-7606-47D9-AE5C-D1A6A69906BC</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Ogg</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12010%2F5"><gtr:id>CFB82685-EE5D-4C0D-B88D-6C57004166CE</gtr:id><gtr:title>Pathogenesis and treatment of cutaneous atopic disease; the interaction between the ipithelium and the innate and adaptive immune response</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12010/5</gtr:grantReference><gtr:abstractText>We are working towards treatment and prevention of immune-mediated skin disease. The skin is often the first point of contact with pathogens and allergens, but relatively little is understood about how the cutaneous immune system clears these challenges. Such knowledge is vitally important to understanding the mechanisms of skin disease and related diseases, and for developing more effective ways of cutaneous drug and vaccine delivery. 
It is increasingly clear that skin barrier dysfunction is an important first step in the development of atopic eczema, one of the commonest skin diseases in the UK, and often associated with asthma and rhinitis. The barrier dysfunction promotes entry of allergens and microbes which eventually lead to skin inflammation. The latter is treated with topical immune suppressants, but these are not curative and also carry risks of side effects.
We wish to understand the steps linking barrier dysfunction and skin inflammation, as these will provide opportunities for new treatments. In particular, we will explore ways to repair barrier function and to understand the roles of novel immune cells in contributing to the inflammation.
These findings will have implications for atopic eczema, but also for other forms of inflammatory skin disease and indeed for the improvement of vaccine delivery in to the skin.</gtr:abstractText><gtr:technicalSummary>Atopic disease affects 20-30% of the UK population and includes atopic eczema, asthma and rhinitis. Current treatments are suppressive, but not curative, and carry risks of side-effects. Since the identification of an association between atopic eczema and null mutations in the gene encoding filaggrin, it has become increasingly clear that events in the epithelium represent critical susceptibility factors in disease pathogenesis. We are working towards an understanding of the pathogenesis of atopic disease, in particular to explain how the epidermal dysfunction associated with filaggrin insufficiency contributes to atopic disease and whether this can be modified therapeutically. We capitalize on the ready access to lesional tissue in humans, and to function within networks and collaborations to maximize opportunities for success. The aim of the research is to understand the pathogenesis of cutaneous atopic disease in order to inform new approaches to disease prevention and treatment. The studies will also contribute to our understanding of the interaction between the epithelium and the innate and adaptive immune response. Emphasis will be focused on: 1) how filaggrin insufficiency promotes atopic inflammation and whether this can be therapeutically modified; 2) characterising innate IL-13 producing cells in human lesional atopic skin and after antigen challenge; 3) understanding mechanisms underlying antigen-specific immunotherapy to modulate immune responses in humans and to translate these findings to patient benefit; 4) investigating mechanisms underlying the cellular immune response to viral antigens in human skin. The experimental design is based on isolation of cells from blood and skin of patients and controls. The cells from skin include keratinocytes, dendritic cell family members (eg Langerhans cells), T cells, innate lymphoid cells. The patients will include those with cutaneous atopic disease and other inflammatory skin diseases, as well as individuals before and after cutaneous antigen challenge. Studies will be undertaken ex vivo and after culture. Interactions between keratinocytes, Langerhans cells and immune effector cells will include examination by expression analyses, mediator production and functional keratinocyte outcomes such as barrier function. Molecular mechanisms underlying these findings will be investigated. As well as contributing to disease and tissue specific questions, these studies will advance the broader University Unit aims of defining the interactions between the innate and adaptive immune responses and the local micro-environment, which in turn will support the development of new approaches to vaccination and treatment.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>902000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Andrew McKenzie LMB Cambridge</gtr:description><gtr:id>5F94E47D-F796-49B0-A1A8-EE9ED3E86628</gtr:id><gtr:impact>new collaboration</gtr:impact><gtr:outcomeId>hhhKuXUxF85-1</gtr:outcomeId><gtr:partnerContribution>Andrew McKenzie provides knowhow and expertise for access to model skin</gtr:partnerContribution><gtr:piContribution>We are working with Andrew McKenzie to identify nuocytes in human and model skin and relate to clinical disease. we provide knowhow and expertise for access to human skin cells.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sri Jayawardanapura</gtr:collaboratingOrganisation><gtr:country>Sri Lanka, Democratic Socialist Republic of</gtr:country><gtr:description>University of Sri Jayawardanapura</gtr:description><gtr:id>F8C43098-AEF2-4453-8AD0-381E55A4BB74</gtr:id><gtr:impact>see relevant sections</gtr:impact><gtr:outcomeId>22B631EF49D-1</gtr:outcomeId><gtr:partnerContribution>Contribution of samples and some analyses</gtr:partnerContribution><gtr:piContribution>Analyses of samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Branch Moody Harvard</gtr:description><gtr:id>C11A41C0-19B2-4281-AC84-671D00AEE249</gtr:id><gtr:impact>Multiple publications and conference presentations</gtr:impact><gtr:outcomeId>56c828def117a1.09548348-1</gtr:outcomeId><gtr:partnerContribution>We collaborate on CD1a-restricted T cell responses. Branch Moody and his team have contributed ideas, samples, experimental work and technical advances.</gtr:partnerContribution><gtr:piContribution>We collaborate on CD1a-restricted T cell responses. We have contributed ideas, samples, experimental work and technical advances.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Medical Molecular Virology</gtr:department><gtr:description>Judy Breuer</gtr:description><gtr:id>6C7519A1-54FF-4073-AE3C-3EACBA61D54A</gtr:id><gtr:impact>see relevant sections</gtr:impact><gtr:outcomeId>777CE819968-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples and analyses</gtr:partnerContribution><gtr:piContribution>Analyses of T cell responses to varicella zoster virus</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Biomedical Research centre Oxford</gtr:description><gtr:id>1490BFB1-0E33-4E0F-B153-5D2614AAE5F6</gtr:id><gtr:impact>Many outputs as detailed in relevant sections</gtr:impact><gtr:outcomeId>9AA2B554C0F-1</gtr:outcomeId><gtr:partnerContribution>Access to equipment and individuals</gtr:partnerContribution><gtr:piContribution>We provided many of the samples and technology for analysis of samples using Biomedical Research Centre equipment.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Paul Klenerman VZV</gtr:description><gtr:id>B6EE102F-8E35-4920-B493-BCBA7533F7D3</gtr:id><gtr:impact>Publications and presentations</gtr:impact><gtr:outcomeId>n58mg5xYF4j-1</gtr:outcomeId><gtr:partnerContribution>Access to samples and discussions.</gtr:partnerContribution><gtr:piContribution>Analysis of varicella zoster virus specific immune respoonses after vaccination</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Blogs</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2B9116A6-E9CE-4E34-BB3A-D20D74EE2087</gtr:id><gtr:impact>Blog discussion of our recent studies</gtr:impact><gtr:outcomeId>56c82ba0d8bac4.20919236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Podcast</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4AE55018-8245-428A-9C89-C0C9DA72E659</gtr:id><gtr:impact>Podcast available through university website and on Youtube</gtr:impact><gtr:outcomeId>56c82b61546b57.79266062</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BRC Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>18980EC2-D86A-4BBC-B6EF-D1880744399D</gtr:id><gtr:impact>Members of public attended and took part in activities run by my group and others

further interest in our research an dsupport from potential participants</gtr:impact><gtr:outcomeId>5437c07ed36f02.35865993</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F077842A-0A0D-4FF2-8D0B-A53D70EAD466</gtr:id><gtr:impact>approx 40 students attended with many questions

Interest from students wanting to study science or medicine. work experience students</gtr:impact><gtr:outcomeId>5437c0c9a08b08.21321587</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C60612DE-6C91-4767-B49C-F7465594D800</gtr:id><gtr:impact>Public lecture describing the science and translational impact of our research. Much positive discussion and feedback - some example comments below:

&amp;quot;Difficult immunology issues presented in a comfortable and easy to understand way. Thank you. &amp;quot;

&amp;quot;Excellent presentation given the complexity of the subject.&amp;quot;

&amp;quot;Very informative, excellent speaker. Thank you.&amp;quot;</gtr:impact><gtr:outcomeId>574e8e68ca0f56.57394427</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=aiFb8CWvy5k&amp;list=PL8hacko-P1Wduo8gAf71vt30nuhpn8OtR</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Abingdon</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>48614252-14F5-4EE9-BA2F-072411691D6E</gtr:id><gtr:impact>80 pupils attended

good informal feedback</gtr:impact><gtr:outcomeId>emeRYytCVwV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>WIMM Public Understanding of Science and Engagement committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>97C3C55A-1432-43C0-BDB4-625B9C3FD7E4</gtr:id><gtr:impact>ongoing activity

ongoing</gtr:impact><gtr:outcomeId>XS9bpW5u3tc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>Janssen collaborative research grant</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>AD4C4B02-0D7C-4256-8B71-075F91A960F2</gtr:id><gtr:outcomeId>e6E7e5rRAQR</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Clinical Research Network (CRN)</gtr:department><gtr:description>Comprehensive Research Network</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>2AF09F62-C51B-46E8-9B66-4261E39AFE5B</gtr:id><gtr:outcomeId>56c82995b49c78.87746474</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Celgene Fellowship</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Celgene</gtr:fundingOrg><gtr:id>A0EB8C15-EF02-438F-B149-F860763FE92B</gtr:id><gtr:outcomeId>56c8306c522e75.31162554</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Johnson and Johnson collaborative research</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>E4CF7548-58A2-48ED-9C6A-D5983690377F</gtr:id><gtr:outcomeId>56c83031bd05b4.24101421</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Anaptysbio Research Grant</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>AnaptysBio</gtr:fundingOrg><gtr:id>F5401F8E-29BD-49F6-9369-DAC867EE9E9F</gtr:id><gtr:outcomeId>589c46b23c9e05.88055981</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>62000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Skin Foundation Grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>British Skin Foundation</gtr:fundingOrg><gtr:id>0C2DDC4B-EAC8-48D4-B6AD-3CA1C74C4A2B</gtr:id><gtr:outcomeId>5437be2724e846.42003339</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>Oxford Biomedical Research Centre</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>269185DA-024C-4E6A-A084-0418CF5FF22C</gtr:id><gtr:outcomeId>C423F5BCA620</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>354000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCB Research grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>354798B8-334E-4EE8-9588-84EF6FC0F0B8</gtr:id><gtr:outcomeId>589c458ed03056.46968063</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>137000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>EXPLORATORY/DEVELOPMENT GRANT</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>1R21AI125886-01</gtr:fundingRef><gtr:id>112021A6-3712-45BF-852F-DFDEE14DD121</gtr:id><gtr:outcomeId>585bdaaed57b30.47168390</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Medical Association</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>118423C1-A768-42C0-9A78-F14D189C8A5A</gtr:id><gtr:outcomeId>hpdkGoswfpr0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>New method for peptide drug discovery</gtr:description><gtr:grantRef>MC_UU_12010/5</gtr:grantRef><gtr:id>E71CBDD1-82CB-45EE-A7AE-E49027CFCFBA</gtr:id><gtr:impact>studies ongoing</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56c82ecce41bb0.15544706</gtr:outcomeId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method for peptide drug discovery</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>New method to characterise whether T cell infiltrates are malignant or inflammatory. New diagnostic test.</gtr:description><gtr:grantRef>MC_UU_12010/5</gtr:grantRef><gtr:id>F3C6D3D5-84B2-4CA3-8BD6-CA959CA0C6E7</gtr:id><gtr:impact>early stage of development</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>5437c1c412ec60.98166998</gtr:outcomeId><gtr:protection>Patent application published</gtr:protection><gtr:title>method to characterise T cell infiltrates</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>technique to determine what serotypes of dengue a person has been infected with</gtr:description><gtr:grantRef>MC_UU_12010/5</gtr:grantRef><gtr:id>DC1DFF5A-3594-4BBB-B64B-0C7C3E216F37</gtr:id><gtr:impact>further work and publication</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>gcJAiJV2inS</gtr:outcomeId><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>method to determine previous dengue serotype infection</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>new approaches to investigation and treatment of atopic disease</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>9930B478-6258-4360-9426-90EC429DB2D3</gtr:id><gtr:outcomeId>HcvHDCfBRii</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Many local/regional clinical guidelines and GP training sessions</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>BA9B657D-BC0A-48CF-A859-686BCA8A7603</gtr:id><gtr:impact>Training and education fo GPs to improve health care delivery</gtr:impact><gtr:outcomeId>56c82c91337fc3.20640012</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Urticaria guidelines committee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>27EB7F24-8791-4025-8B3A-C39E66DE561E</gtr:id><gtr:impact>The guidelines will impact on healthcare internationally</gtr:impact><gtr:outcomeId>56c82bf88c3825.22957321</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>I run many clinical trials in Oxford to translate our findings towards clinical practice</gtr:description><gtr:id>DBBFF4C3-ED79-4707-A1DD-6C201A0B8108</gtr:id><gtr:impact>As trials progress, these will introduce new forms of treatment.</gtr:impact><gtr:outcomeId>56c82d69386633.28890179</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Many clinical trials</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We observed that staphylococcal superantigen facilitates antigen presentation of allergen by epithelial cells. This potentially explains a clinical observation seen in individuals with atopic dermatitis, that flares of disease are often associated with infection. The underlying mechanisms were characterised. I believe this is important for understanding of disease and for the development of new treatment approaches (recent award of MRC Experimental Medicine 2 funding to take this into a proof-of-principle clinical trial).</gtr:description><gtr:id>5D7880AB-FB66-466C-8674-A0EFA04BA17E</gtr:id><gtr:impact>We hope that this will provide patient benefit</gtr:impact><gtr:outcomeId>963A8CDB66F</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Idea that combined allergen and anti-bacterial approaches may benefit patients with atopic disease</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A high throughput method to identify peptides ligands of any target, form a large library.</gtr:description><gtr:id>F0BF2E45-36C9-453E-A112-3440C2304A85</gtr:id><gtr:impact>Orbit Discovery spin out has licensed the technology</gtr:impact><gtr:outcomeId>585bdcd71dec74.44899458</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>High throughput peptide display technology</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Allergen-specific T cells were derived from human peripheral blood and used to show an interaction with S.aureus. This has lead to the award of an MRC Experimental Medicine 2 grant for a proof of concept clinical trial.</gtr:description><gtr:id>DC6971A5-347E-4A65-A5C2-B2FB6C61595C</gtr:id><gtr:impact>many outputs - see relevant sections</gtr:impact><gtr:outcomeId>7D41E1E1024</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Allergen-specific T cells</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Orbit Discovery Ltd</gtr:companyName><gtr:description>Peptide drug discovery company</gtr:description><gtr:id>8F918873-C2D7-4D5D-B9DD-847855E73DA2</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56c82db035b381.12486657</gtr:outcomeId><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>FA39FDF4-9479-4443-984A-B0DBCCA6182D</gtr:id><gtr:title>Bee venom processes human skin lipids for presentation by CD1a.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b35c1f191240d89a521fb16991424bd0"><gtr:id>b35c1f191240d89a521fb16991424bd0</gtr:id><gtr:otherNames>Bourgeois EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>56c826cf7fd094.32097975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7288040-A532-472C-B0D6-78978E2A78BB</gtr:id><gtr:title>Molecular characterisation of varicella zoster virus genotypes in Sri Lanka.</gtr:title><gtr:parentPublicationTitle>The Ceylon medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4a6dd5de3a715dfe141b2c325690719"><gtr:id>c4a6dd5de3a715dfe141b2c325690719</gtr:id><gtr:otherNames>Lohitharajah J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-0875</gtr:issn><gtr:outcomeId>5437b9f66cd092.20142764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE199346-7159-41B3-88FE-CE19622D7AF6</gtr:id><gtr:title>Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87abb607a6d8c07e3ff22921a3deb991"><gtr:id>87abb607a6d8c07e3ff22921a3deb991</gtr:id><gtr:otherNames>Jayaratne SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>pm_13469_29_23167997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EF2D22E-E577-40A6-BF62-5B0EC7CF7B3E</gtr:id><gtr:title>Interleukin-33, friend and foe in type-2 immune responses.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ca174d7cdc7d1c82054fcfe145a9b2a"><gtr:id>9ca174d7cdc7d1c82054fcfe145a9b2a</gtr:id><gtr:otherNames>Hardman C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>585bd909e7a124.84078874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>789E5E97-48F5-4E5A-BA35-E71191A360F2</gtr:id><gtr:title>MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88f7632d46b6836b8594e227c55d3fc9"><gtr:id>88f7632d46b6836b8594e227c55d3fc9</gtr:id><gtr:otherNames>Oliphant CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>5437b975310946.97955386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4752031F-6B64-4728-A518-C9B95662002F</gtr:id><gtr:title>Polymorphisms of Transporter Associated with Antigen Presentation, Tumor Necrosis Factor-a and Interleukin-10 and their Implications for Protection and Susceptibility to Severe Forms of Dengue Fever in Patients in Sri Lanka.</gtr:title><gtr:parentPublicationTitle>Journal of global infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/190c5eaa5976a93358a138e588182166"><gtr:id>190c5eaa5976a93358a138e588182166</gtr:id><gtr:otherNames>Fernando AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0974-777X</gtr:issn><gtr:outcomeId>56c826cd8dbbc0.93834017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8C9BB9F-B7B2-4FC3-81BC-435833F86F65</gtr:id><gtr:title>Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e200c51da2b19d2de19a97e9e8cfc48"><gtr:id>1e200c51da2b19d2de19a97e9e8cfc48</gtr:id><gtr:otherNames>Kortekaas Krohn I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>5a96888c64f296.91894550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>975BBD9E-68DE-4427-85B8-A0A2903B0DDC</gtr:id><gtr:title>IL-17 Receptor A Maintains and Protects the Skin Barrier To Prevent Allergic Skin Inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f973b6970aa4bd06f6bcdfe946d97366"><gtr:id>f973b6970aa4bd06f6bcdfe946d97366</gtr:id><gtr:otherNames>Floudas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5a96888c92c7d8.56969046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D176A77E-456C-4A67-8E7D-B8A1486EB349</gtr:id><gtr:title>Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of the American Academy of Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8cbd8e168571c0a67a1a4ebaa06aedc"><gtr:id>c8cbd8e168571c0a67a1a4ebaa06aedc</gtr:id><gtr:otherNames>Thomas KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0190-9622</gtr:issn><gtr:outcomeId>585bd90a350675.50316217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1953B55-8ACB-4C04-8EF5-77024A1EE2E5</gtr:id><gtr:title>Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2abd7ea4a2d38b6996263dc56bf14550"><gtr:id>2abd7ea4a2d38b6996263dc56bf14550</gtr:id><gtr:otherNames>Salimi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56c826ce21b895.27592657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02F385BF-CBE7-41BA-829B-C882B13D3222</gtr:id><gtr:title>Cysteinyl leukotriene Eactivates human group 2 innate lymphoid cells and enhances the effect of prostaglandin Dand epithelial cytokines.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2abd7ea4a2d38b6996263dc56bf14550"><gtr:id>2abd7ea4a2d38b6996263dc56bf14550</gtr:id><gtr:otherNames>Salimi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5a96888d70a939.65010362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>700CF7AD-9BE7-4DB8-A31B-2CE87F8943D1</gtr:id><gtr:title>Innate lymphoid cells and the skin.</gtr:title><gtr:parentPublicationTitle>BMC dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2abd7ea4a2d38b6996263dc56bf14550"><gtr:id>2abd7ea4a2d38b6996263dc56bf14550</gtr:id><gtr:otherNames>Salimi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-5945</gtr:issn><gtr:outcomeId>56c826cfd54dc2.92652829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6679FE3-4B3D-4EEE-B629-378CCD26B7FC</gtr:id><gtr:title>Suppression of virus specific immune responses by IL-10 in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>5437bb57a03a71.69008736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAEDDB95-5165-45D6-964D-9BEB30F7B3FF</gtr:id><gtr:title>Regulatory T-cells in acute dengue viral infection.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe674ec3c39102495bf68bcb73443197"><gtr:id>fe674ec3c39102495bf68bcb73443197</gtr:id><gtr:otherNames>Jayaratne HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>5a96888c2dbce9.02562329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3D24428-9B4A-4027-807F-94DED5EA040E</gtr:id><gtr:title>Patterns and causes of liver involvement in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d706dc489c4e4bc426abc0b05129de2a"><gtr:id>d706dc489c4e4bc426abc0b05129de2a</gtr:id><gtr:otherNames>Fernando S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>585bd90c0e66d0.12142693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78D79917-B014-4B24-99F6-113033593259</gtr:id><gtr:title>Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a25fe729ac3cfa6c00ed80a3d003c92"><gtr:id>4a25fe729ac3cfa6c00ed80a3d003c92</gtr:id><gtr:otherNames>Subramaniam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56c826ce4754e1.62645458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A9EA3C4-CF0D-4063-9E3D-E2C7E21D9B4F</gtr:id><gtr:title>Role of skin homing T cells in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>Annals of translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2305-5839</gtr:issn><gtr:outcomeId>56c82741c863e1.14525155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6772560F-670D-47F6-84C6-367220D5FD29</gtr:id><gtr:title>Dengue NS1 antigen as a marker of severe clinical disease.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de3b6ecf7d3b98a3ccd15df532e4b88f"><gtr:id>de3b6ecf7d3b98a3ccd15df532e4b88f</gtr:id><gtr:otherNames>Paranavitane SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>56c826d047f170.88760601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B402DA67-2304-4A06-980D-23DB0AEEA8F2</gtr:id><gtr:title>Cytokine regulation of the epidermal barrier.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>5437bc018838e3.51616296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>365F9D81-6469-40F7-BEF0-76C5E239494C</gtr:id><gtr:title>Lipid-specific T cells and the skin.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491c3e1b512dfea6622f88c5f22471f8"><gtr:id>491c3e1b512dfea6622f88c5f22471f8</gtr:id><gtr:otherNames>Jarrett R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>585bd90a1a7570.48567394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44061FF3-8BD3-4F42-9ABF-D5895264CBB1</gtr:id><gtr:title>The Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d303595cecc95b47227c65d510287e"><gtr:id>05d303595cecc95b47227c65d510287e</gtr:id><gtr:otherNames>Vukmanovic-Stejic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>56c826cf2a82a6.12606276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6A1596D-E842-4CCA-B517-307792D5BE1D</gtr:id><gtr:title>Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d303595cecc95b47227c65d510287e"><gtr:id>05d303595cecc95b47227c65d510287e</gtr:id><gtr:otherNames>Vukmanovic-Stejic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5437bc69e2c706.06129952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6392B47D-39B0-4CFB-AF71-F217E4EDC8D7</gtr:id><gtr:title>Sphingosine 1-phosphate in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2da03c5464ef74d5853af0206a3a87e1"><gtr:id>2da03c5464ef74d5853af0206a3a87e1</gtr:id><gtr:otherNames>Gomes L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c826d00b81c7.01953251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB16FD9B-70B9-4743-92BE-8E3624BF9A31</gtr:id><gtr:title>Platelet activating factor contributes to vascular leak in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea2f0350613aecf7b2f3c4ac416db28"><gtr:id>6ea2f0350613aecf7b2f3c4ac416db28</gtr:id><gtr:otherNames>Jeewandara C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>56c826cf56dd58.17542132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC87BDC2-EDA4-4076-9235-793E8FA09D69</gtr:id><gtr:title>Histamine exerts multiple effects on expression of genes associated with epidermal barrier function.</gtr:title><gtr:parentPublicationTitle>Journal of investigational allergology &amp; clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-9068</gtr:issn><gtr:outcomeId>5437b8f236cdd1.63190943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E741F577-A118-420F-A661-B7DB08B8E255</gtr:id><gtr:title>Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/972bcd649809975a6ae6579df5d505cb"><gtr:id>972bcd649809975a6ae6579df5d505cb</gtr:id><gtr:otherNames>Xue L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56c826cfa99691.71469226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B450C0A-6E7E-43B9-9FA3-BFAB149CF0B8</gtr:id><gtr:title>Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infection.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea2f0350613aecf7b2f3c4ac416db28"><gtr:id>6ea2f0350613aecf7b2f3c4ac416db28</gtr:id><gtr:otherNames>Jeewandara C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>56c826cef40db7.86833258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F82A1A7-7027-487E-8EAD-7F3B0EAB2B82</gtr:id><gtr:title>T cell responses in dengue viral infections.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>doi_13469_013_10_023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68327D3F-0731-471A-B46C-F8ECF6997015</gtr:id><gtr:title>Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491c3e1b512dfea6622f88c5f22471f8"><gtr:id>491c3e1b512dfea6622f88c5f22471f8</gtr:id><gtr:otherNames>Jarrett R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>56c74243a9f224.34434137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>962B68B8-0DD9-4A38-BD3E-54E7513867D8</gtr:id><gtr:title>Dengue NS1 antigen contributes to disease severity by inducing interleukin (IL)-10 by monocytes.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc0cb6b857352042eafc7e1efdac898e"><gtr:id>cc0cb6b857352042eafc7e1efdac898e</gtr:id><gtr:otherNames>Adikari TN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>56c826cdecf7b9.79048405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71550E56-CD74-4A7A-839D-AD13208E2D84</gtr:id><gtr:title>Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f05f075d4358c2d78b4fd9bd1b68a270"><gtr:id>f05f075d4358c2d78b4fd9bd1b68a270</gtr:id><gtr:otherNames>Saunders SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56c826ce888664.04084412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDB195A4-4EA1-4F14-A393-EC8F219AA367</gtr:id><gtr:title>Pathogenesis of vascular leak in dengue virus infection.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>5a96888d071202.56084076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E312ABD6-8FAA-4F6A-AAFA-553ECB471B62</gtr:id><gtr:title>Histamine enhances keratinocyte-mediated resolution of inflammation by promoting wound healing and response to infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>5437b9463d9a25.37241977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC03629-48F8-43D5-86C4-368537ADE4FA</gtr:id><gtr:title>Filaggrin-insufficiency in keratinocytes influences responsiveness of allergen-specific T cells to cognate antigen and compounds barrier function deficiency.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a11eaaa4eac4018346f00a2d8d401fa4"><gtr:id>a11eaaa4eac4018346f00a2d8d401fa4</gtr:id><gtr:otherNames>Marwah I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>doi_13469_014_04_011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96E81DDE-6F93-4B26-8C06-3B600945EB19</gtr:id><gtr:title>Secretory phospholipase A2 in the pathogenesis of acute dengue infection.</gtr:title><gtr:parentPublicationTitle>Immunity, inflammation and disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea2f0350613aecf7b2f3c4ac416db28"><gtr:id>6ea2f0350613aecf7b2f3c4ac416db28</gtr:id><gtr:otherNames>Jeewandara C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-4527</gtr:issn><gtr:outcomeId>5a96888d3722f0.11500792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07F07720-CE74-4656-BE02-2FC42590496A</gtr:id><gtr:title>Deficiency of filaggrin regulates endogenous cysteine protease activity, leading to impaired skin barrier function.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49757b99ad1001a2e87e2c4bf815f1d0"><gtr:id>49757b99ad1001a2e87e2c4bf815f1d0</gtr:id><gtr:otherNames>Wang XW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>5a96888cc8faa9.39724528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DBB67C7-165B-4E3C-8D06-AAC0FDF086A2</gtr:id><gtr:title>Combinatorial HLA-peptide bead libraries for high throughput identification of CD8? T cell specificity.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa6b6c24080c1135d3653d8e343c7a89"><gtr:id>fa6b6c24080c1135d3653d8e343c7a89</gtr:id><gtr:otherNames>Pan X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>doi_13469_013_11_023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91E88DF1-36FD-4E6E-A287-ED9B56E4CAF7</gtr:id><gtr:title>Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/972bcd649809975a6ae6579df5d505cb"><gtr:id>972bcd649809975a6ae6579df5d505cb</gtr:id><gtr:otherNames>Xue L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>doi_13469_013_10_056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>814DA3BA-CA1A-48A6-83B8-7280183699F1</gtr:id><gtr:title>Enhanced isolation of lymphoid cells from human skin.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2abd7ea4a2d38b6996263dc56bf14550"><gtr:id>2abd7ea4a2d38b6996263dc56bf14550</gtr:id><gtr:otherNames>Salimi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>56c74243d552d9.12130295</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A09C777F-20AD-4CB2-9875-4149010B01E4</gtr:id><gtr:title>Therapeutic vaccines for allergic disease.</gtr:title><gtr:parentPublicationTitle>NPJ vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2059-0105</gtr:issn><gtr:outcomeId>5a96888be3b6e0.58513405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CFEA35F-E63D-4032-A5AA-9F55E7041329</gtr:id><gtr:title>Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5302b7eca84d4e22120ea427b25f946b"><gtr:id>5302b7eca84d4e22120ea427b25f946b</gtr:id><gtr:otherNames>Ormerod AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>56c826cebba143.60465729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B5F2906-D984-4C19-AC3D-ECDC0DD49E7A</gtr:id><gtr:title>Expansion of highly activated invariant natural killer T cells with altered phenotype in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5253ccac976e8e8fdf9eba0567d80417"><gtr:id>5253ccac976e8e8fdf9eba0567d80417</gtr:id><gtr:otherNames>Kamaladasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>56c742437cdbb7.91884216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10C9D362-EA46-4AC2-9CBF-248A183A066B</gtr:id><gtr:title>Serum IL-10 as a marker of severe dengue infection.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>pm_13469_29_23883139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3418C98A-F508-4D3B-A728-37D9A763B7AE</gtr:id><gtr:title>Linking genotype to phenotype on beads: high throughput selection of peptides with biological function.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63dd7815b106ce172e0bae9d5d1fe643"><gtr:id>63dd7815b106ce172e0bae9d5d1fe643</gtr:id><gtr:otherNames>Huang LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5437bae90e3f19.66551208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBC70B63-C23C-4B94-A738-F66D0486259D</gtr:id><gtr:title>A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2abd7ea4a2d38b6996263dc56bf14550"><gtr:id>2abd7ea4a2d38b6996263dc56bf14550</gtr:id><gtr:otherNames>Salimi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>doi_13469_m_20130351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E485AE41-4DC5-4F66-97F6-41B781252AC7</gtr:id><gtr:title>The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>5437b975669239.46183866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B758790-2394-4301-ACAD-915579EAA1BC</gtr:id><gtr:title>Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61a8a8769f57bfb80d01cbd83c6b55f8"><gtr:id>61a8a8769f57bfb80d01cbd83c6b55f8</gtr:id><gtr:otherNames>Cheung KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>585bd909b3c719.75237703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDA6C67-D3E2-4111-9493-6054C8E8F1B4</gtr:id><gtr:title>Penicillin to prevent recurrent leg cellulitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8cbd8e168571c0a67a1a4ebaa06aedc"><gtr:id>c8cbd8e168571c0a67a1a4ebaa06aedc</gtr:id><gtr:otherNames>Thomas KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_13469_29_23635049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC4541EC-C616-4C70-873B-ADB088822F16</gtr:id><gtr:title>Cellular and cytokine correlates of severe dengue infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13469_29_23209731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A401BD8-892D-4A8B-8815-5DC837E42405</gtr:id><gtr:title>CD1a presentation of endogenous antigens by group 2 innate lymphoid cells.</gtr:title><gtr:parentPublicationTitle>Science immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e1930c9db358c717fa9c55f59f2a171"><gtr:id>8e1930c9db358c717fa9c55f59f2a171</gtr:id><gtr:otherNames>Hardman CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2470-9468</gtr:issn><gtr:outcomeId>5a96888b8b3727.02450196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B754389B-0D5B-4AEF-BD97-5665331F9572</gtr:id><gtr:title>Change in Dengue and Japanese Encephalitis Seroprevalence Rates in Sri Lanka.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ea2f0350613aecf7b2f3c4ac416db28"><gtr:id>6ea2f0350613aecf7b2f3c4ac416db28</gtr:id><gtr:otherNames>Jeewandara C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c826cdbae4c6.25840781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F40471-5755-41CF-9986-CC76A0A165C1</gtr:id><gtr:title>Lipopolysaccharide acts synergistically with the dengue virus to induce monocyte production of platelet activating factor and other inflammatory mediators.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5253ccac976e8e8fdf9eba0567d80417"><gtr:id>5253ccac976e8e8fdf9eba0567d80417</gtr:id><gtr:otherNames>Kamaladasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>585bd90be616b2.86103220</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12010/5</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>